DPx

DPx Holdings was a leading global provider of integrated services to the pharmaceutical and biotechnology industries, primarily operating through its business units Patheon and DSM Fine Chemicals. Formed in 2014 as a joint venture between JLL Partners and Royal DSM, the company specialized in contract development and manufacturing services (CDMO). Its offerings spanned the entire drug development lifecycle, including API manufacturing, formulation development, and commercial-scale production. In 2017, DPx Holdings was acquired by Thermo Fisher Scientific for approximately $7.2 billion, significantly expanding Thermo Fisher's presence in the pharma services market.